Pharmaceutical intermediates
Ticagrelor Intermediates
7 pharmaceutical intermediates for Ticagrelor. Indication: Stroke; Acute Coronary Syndrome ; Myocardial Infarction; Peripheral Vascular Disease.
About Ticagrelor
- Originator
- AstraZeneca
- Indication
- Stroke; Acute Coronary Syndrome ; Myocardial Infarction; Peripheral Vascular Disease
- Approved Date
- 09/03/2015
- DS/DP
- 04/30/2025
Available intermediates
7 intermediates currently listed for Ticagrelor. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4,6-Dichloro-2-(propylthio)pyrimidin -5-amine | 145783-15-9 | / | / |
| 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro -3aH-cyclopenta[d][1,3]dioxol -4-yloxy)ethanol L-tataric acid | 376608-65-0 | / | / |
| (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium(2R)hydroxy(phenyl)ethanoate | 376608-71-8 | / | / |
| Ethanol, 2-[[(3aR,4S,6R,6aS)-6-[[5-aMino-6-chloro-2-(propylthio)-4-pyriMidinyl]aMino]tetrahydro-2,2-diMethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]- | 376608-74-1 | / | / |
| (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine hydrochloride | 1156491-10-9 | / | / |
| Cyclopropanamine,2-(3,4-difluorophenyl)-(1R,2S) -(2R,3R)-2,3-dihydroxybutanedioate (1:1) | 220352-39-6 | / | / |
| 2-[[(3aS,4R,6S,6aR)-4-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-6-yl]oxy]ethanol | 274693-26-4 | / | / |
Building toward Ticagrelor?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →